Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent

Cancer Research

Volumn 59, Issue 16, 1999, Pages 3998-4003

  Pedley, R Barbara ^a   Sharma, Surinder K ^a   Boxer, Geoffrey M ^a   Boden, Robert ^a   Stribbling, Stephen M ^b   Davies, Lawrence ^b   Springer, Caroline J ^b   Begent, Richard H J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CARBOXYPEPTIDASE G2; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; COLORECTAL CANCER; DRUG DISTRIBUTION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR BLOOD FLOW; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; GAMMA-GLUTAMYL HYDROLASE; GLUTAMATES; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS; XANTHENES; XANTHONES;

EID: 0033567097     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jain, R. K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst., 81: 570-576, 1989.
2. Pedley, R. B. Pharmacokinetics of monoclonal antibodies: implications for their use in cancer therapy. Clin. Immunother., 6: 54-67, 1996.
3. Baxter, L. T., and Jain, R. K. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br. J. Cancer, 73: 447-456, 1996.
4. Bagshawe, K. D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer, 56: 531-532, 1987.
5. Senter, P. D., Wallace, P. M., Svensson, H. P., Vrudhula, V. M., Kerr, D. E., Hellstrom, I., and Hellstrom, K. E. Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chem., 4: 3-9, 1993.
6. Niculescu-Duvaz, I., and Springer, C. J. Antibody-directed enzyme prodrug therapy (ADEPT): a targeting strategy in cancer chemotherapy. Curr. Med. Chem., 2: 687-706, 1995.
7. Springer, C. J., Niculescu-Duvaz, I., and Pedley, R. B. Novel prodrugs of alkylating agents derived from 2-fluoro-and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. J. Med. Chem., 37: 2361-2370, 1994.
8. Blakey, D. C., Burke, P. J., Davies, D. H., Dowell, R. I., East, S. J., Eckersley, K. P., Fitton, J. E., McDaid, J., Melton, R. G., Niculescu-Duvaz, I., Pinder, P. E., Sharma, S. K., Wright, A. F., and Springer, C. J. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Cancer Res., 56: 3287-3292, 1996.
9. Bagshawe, K. D. Sharma, S. K., Springer, C. J., and Antoniw, P. Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumor Targeting, I: 17-29, 1995.
10. Martin, J., Stribbling, S. M., Poon, G. K., Begent, R. H. J., Napier, M., Sharma, S. K., and Springer, C. J. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a Phase I clinical trial. Cancer Chemother. Pharmacol., 40: 189-201, 1997.
11. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 57: 1829-1834, 1997.
12. Zwi, L. J., Baguley, B. C., Gavin, J. B., and Wilson, W. R. The morphological effects of the anti-tumour agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on colon 38 mouse tumour. Pathology, 24: 161-169, 1994.
13. Pedley, R. B., Begent, R. H. J., Boden, J. A., Boxer, G. M., Boden, R., and Keep, P.A. Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonie xenograft model. Int. J. Cancer, 57: 830-835, 1994.
14. Pedley, R. B., Boden, J. A., Boden, R., Boxer, G. M., Flynn, A. A., Keep, P. A., and Begent, R. H. J. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow modifying agents. Cancer Res., 56: 3293-3300, 1996.
15. Ching, L-M., Joseph, W. R., Crosier, K. E., and Baguley, B. C. Induction of tumour necrosis factor-α in human and murine cells by the flavone acetic acid analogue 5,6-dimethyhanthenone-4-acetic acid. Cancer Res., 54: 870-872, 1994.
16. Springer, C. J., Antoniw, P., Bagshawe, K. D., Searle, F., Bisset, M. F., and Jarman, M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem., 33: 677-681, 1990.
17. Lane, D. M., Eagle, K. F., Begent, R. H. J., Hope-Stone, L. D., Green, A. J., Casey, J. L., Keep, P. A., Kelly, A. M. B., Ledermann, J. A., Glaser, M. G., and Hilson, A. J. W. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: Phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br. J. Cancer, 70: 521-525, 1994.
18. Melton, R. G., Boyle, J. M. B., Rogers, G. T., Burke, P., Bagshawe, K. D., and Sherwood, R. F. Optimisation of a small scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J. Immunol. Methods, 158: 49-56, 1993.
19. Sherwood, R. F., Melton, R. G., Alwan, S. M., and Hughes, P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS16: use of a novel triazine dye affinity method. Eur. J. Biochem., 148: 447-453, 1985.
20. 131I anti-CEA antibody in a colonic xenograft model. Br. J. Cancer, 68: 69-73, 1993.
21. Stribbling, S. M., Martin, J., Pedley, R. B., Boden, J. A., Sharma, S. K., and Springer, C. J. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Cancer Chemother. Pharmacol., 40: 277-284, 1997.
22. Looney, W. B., Mayo, A. A., Allen, P. M., Morrow, J. Y., and Morris, H. P. A mathematical evaluation of tumour growth curves in rapid, intermediate and slow growing rat hepatoma. Br. J. Cancer, 27: 341-344, 1973.
23. Lee, E., and Desu, M. A computer program for comparing K samples with right censored data. Comput. Prog. Biomed., 2: 315-321, 1972.
24. Flynn, A. A., Green, A. J., Boxer, G. M., Casey, J., Pedley, R. B., and Begent, R. H. J. A novel technique, using radioluminography, for the measurement of uniformity of radiolabeled antibody distribution on a colorectal cancer xenograft model. Int. J. Radiat. Oncol. Biol. Phys., 43: 183-189, 1999.
25. Sharma, S. K., Bagshawe, K. D., Springer, C. J., Burke, P. J., Rogers, G. T., Boden, J. A., Antoniw, P., Melton, R. G., and Sherwood, R. F. Antibody-directed Enzyme Prodrug Therapy (ADEPT): a three phase system. Dis. Markers, 9: 225-231, 1991.
26. Michael, N. P., Chester, K. A., Melton, R. G., Robson, L., Nicholas, W., Boden, J. A., Pedley, R. B., Begent, R. H. J., Sherwood, R. F., and Minton, N. M. In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology, 2: 47-57, 1996.
27. Pruijn, F. B., van Dalen, M., Holford, N. H. G., and Wilson, W. R. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol., 39: 541-546, 1997.
28. Sersa, G., Willingham, V., and Milas, L. Anti-tumour effects of tumour necrosis factor alone or combined with radiotherapy. Int. J. Cancer, 42: 129-134, 1988.
29. Antoniw, P., Springer, C. J., Bagshawe, K. D., Searle, F., Melton, R. G., Rogers, G. T., Burke, P. J., and Sherwood, R. F. Disposition of the prodrug 4-(bis(2-chloroethy)amino) benzoyl-L-glulamic acid and its active parent drug in mice. Br. J. Cancer, 62: 909-914, 1990.